Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDRNASDAQ:CORTNASDAQ:LGNDNASDAQ:TCDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDRAlder Biopharmaceuticals$18.88$18.88$8.39▼$19.12$1.58B2.645.12 million shsN/ACORTCorcept Therapeutics$69.31-5.6%$72.79$29.42▼$117.33$7.78B0.161.18 million shs1.45 million shsLGNDLigand Pharmaceuticals$112.56-1.0%$108.01$81.74▼$129.90$2.19B0.84117,993 shs109,742 shsTCDATricida$0.13$0.09▼$13.85$6.01M0.2217.62 million shs31.13 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDRAlder Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%CORTCorcept Therapeutics+0.25%-1.18%-6.01%-20.16%+125.92%LGNDLigand Pharmaceuticals-0.41%-1.12%+10.19%+8.45%+34.92%TCDATricida0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALDRAlder BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACORTCorcept Therapeutics4.7096 of 5 stars3.51.00.04.22.84.21.9LGNDLigand Pharmaceuticals4.7321 of 5 stars3.53.00.04.41.63.31.9TCDATricidaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDRAlder Biopharmaceuticals 0.00N/AN/AN/ACORTCorcept Therapeutics 3.00Buy$138.2599.47% UpsideLGNDLigand Pharmaceuticals 3.00Buy$146.1429.84% UpsideTCDATricida 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALDR, LGND, TCDA, and CORT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.005/6/2025CORTCorcept TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$135.005/6/2025CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$150.00 ➝ $145.004/10/2025LGNDLigand PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$143.004/3/2025CORTCorcept TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$128.00 ➝ $131.004/1/2025CORTCorcept TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $142.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDRAlder Biopharmaceuticals$1.62M977.10N/AN/A$1.61 per share11.73CORTCorcept Therapeutics$675.04M10.89$1.17 per share59.10$6.49 per share10.68LGNDLigand Pharmaceuticals$167.13M12.99$1.59 per share70.75$43.95 per share2.56TCDATricidaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDRAlder Biopharmaceuticals-$296.43M-$4.87N/AN/AN/AN/A-226.13%-66.86%N/ACORTCorcept Therapeutics$141.21M$1.1659.7537.46N/A19.33%20.40%16.64%8/4/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$7.12N/A30.34N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)TCDATricida-$176.57M-$2.36N/AN/AN/AN/AN/A-103.81%N/ALatest ALDR, LGND, TCDA, and CORT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/5/2025Q1 2025CORTCorcept Therapeutics$0.17$0.17N/A$0.17$177.93 million$157.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDRAlder BiopharmaceuticalsN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ATCDATricidaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDRAlder Biopharmaceuticals1.748.948.94CORTCorcept TherapeuticsN/A3.072.96LGNDLigand PharmaceuticalsN/A5.275.02TCDATricidaN/A4.874.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDRAlder BiopharmaceuticalsN/ACORTCorcept Therapeutics93.61%LGNDLigand Pharmaceuticals91.28%TCDATricidaN/AInsider OwnershipCompanyInsider OwnershipALDRAlder Biopharmaceuticals15.40%CORTCorcept Therapeutics20.50%LGNDLigand Pharmaceuticals7.00%TCDATricida35.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDRAlder Biopharmaceuticals20283.84 millionN/AOptionableCORTCorcept Therapeutics300106.04 million84.31 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.94 millionOptionableTCDATricida5755.67 million35.85 millionNot OptionableALDR, LGND, TCDA, and CORT HeadlinesRecent News About These CompaniesTricida CEO to Pay $14 Million in Class Suit Over Drug ProgressMarch 4, 2025 | news.bloomberglaw.comNPatrick G Enright's Net WorthMay 5, 2024 | benzinga.comSierraConstellation Partners Receives Industry Recognition for Work with TricidaFebruary 6, 2024 | finance.yahoo.comTricida Inc (TCDAQ)January 13, 2024 | es.investing.comEmerging Therapies in the Treatment of Clostridium difficile-Associated DiseaseMay 30, 2023 | medscape.comMVaniam Group Hires Paula Franson to Lead Clinical Strategy & Solutions - Yahoo FinanceApril 17, 2023 | news.google.comNMetabolic Acidosis Market to Witness Growth by 2032, Estimates ... - Digital JournalApril 17, 2023 | news.google.comNReal-time PCR as a Diagnostic Tool for Bacterial DiseasesApril 12, 2023 | medscape.comMChronic Kidney Disease Drugs Market Expected To Propel Market ... - Digital JournalApril 10, 2023 | news.google.comNChronic Kidney Disease Drugs Market Huge Growth in Future ... - Digital JournalApril 6, 2023 | news.google.comNTricida Heading For Ch. 11 Confirmation Fight With Creditors - Law360March 24, 2023 | news.google.comNAlicia Dixon Joins COPILOT Provider Support Services as VP of Strategy Development & Execution - Yahoo FinanceMarch 14, 2023 | news.google.comNAlicia Dixon Joins COPILOT Provider Support Services as VP of ... - Yahoo FinanceMarch 14, 2023 | news.google.comNTricida Heads To Ch. 11 Mediation Over Creditor Plan Issues - Law360March 6, 2023 | news.google.comNTroubled Adamis To Merge With Private DMK, Focus On ... - ScripMarch 1, 2023 | news.google.comNRelease Opt Out Trips Up Tricida Ch. 11 Disclosure Approval - Law360February 27, 2023 | news.google.comNRenibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale - Law360February 21, 2023 | news.google.comNSTONEHILL CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 4th ... - GuruFocus.comFebruary 18, 2023 | news.google.comNTop 5 4th Quarter Trades of ORBIMED ADVISORS LLC - GuruFocus.comFebruary 18, 2023 | news.google.comNTricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo FinanceFebruary 14, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALDR, LGND, TCDA, and CORT Company DescriptionsAlder Biopharmaceuticals NASDAQ:ALDRAlder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.Corcept Therapeutics NASDAQ:CORT$69.31 -4.09 (-5.57%) Closing price 04:00 PM EasternExtended Trading$70.69 +1.38 (+2.00%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Ligand Pharmaceuticals NASDAQ:LGND$112.56 -1.12 (-0.99%) Closing price 04:00 PM EasternExtended Trading$112.63 +0.07 (+0.06%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Tricida NASDAQ:TCDATricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.